BioWorld

Nov. 18, 2003

GenPath, Merck Sign Potential $100M Deal For Cancer Drugs

Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, excluding royalties. (BioWorld Today) Read More

Allos Presents RSR13 Data; NDA Completion Expected This Year

Anadys Files $86.25M IPO; HCV Drug Duo Leads Pack

MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi

Correction

Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2026.

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...